Gene: Cdkn2b (cyclin-dependent kinase inhibitor 2B) Rattus norvegicus
Analyze
Symbol:
Cdkn2b
Name:
cyclin-dependent kinase inhibitor 2B
Description:
Predicted to have cyclin-dependent protein serine/threonine kinase inhibitor activity and protein kinase binding activity. Involved in several processes, including aging; negative regulation of cell cycle G1/S phase transition; and negative regulation of glial cell proliferation. Localizes to the nucleus. Used to study endometrial cancer and renal cell carcinoma. Human ortholog(s) of this gene implicated in carcinoma (multiple); erythema infectiosum; hematologic cancer (multiple); open-angle glaucoma; and urinary bladder cancer. Orthologous to human CDKN2B (cyclin dependent kinase inhibitor 2B); PARTICIPATES IN G1/S transition pathway; cell cycle pathway, mitotic; small cell lung carcinoma pathway; INTERACTS WITH (+)-schisandrin B; 1-naphthyl isothiocyanate; 2-acetamidofluorene.
Type:
protein-coding
RefSeq Status:
VALIDATED
Also known as:
cyclin dependent kinase inhibitor 2B; Cyclin dependent kinase inhibitor 2B (p15 inhibits CDK4); Cyclin dependent kinase inhibitor 2B (p15, inhibits CDK4); cyclin-dependent kinase 4 inhibitor B; cyclin-dependent kinase inhibitor 2B (p15, inhibits CDK4); p14-INK4b; p15; p15-INK4b
Orthologs:
Species
Gene symbol and name
Data Source
Assertion derived from
less info ...
Orthologs 1
Homo sapiens (human):
CDKN2B (cyclin dependent kinase inhibitor 2B) HGNC
EggNOG, Ensembl, HomoloGene, Inparanoid, NCBI, OrthoDB, OrthoMCL, PhylomeDB, Treefam
Mus musculus (house mouse):
Cdkn2b (cyclin dependent kinase inhibitor 2B) HGNC
Treefam, EggNOG, OrthoMCL, NCBI, HomoloGene, Inparanoid, PhylomeDB, OrthoDB, Ensembl
Chinchilla lanigera (long-tailed chinchilla):
Cdkn2b (cyclin dependent kinase inhibitor 2B) Transitive Ortholog Pipeline
Transitive Ortholog Pipeline
Pan paniscus (bonobo/pygmy chimpanzee):
CDKN2B (cyclin dependent kinase inhibitor 2B) Transitive Ortholog Pipeline
Transitive Ortholog Pipeline
Canis lupus familiaris (dog):
CDKN2B (cyclin dependent kinase inhibitor 2B) Transitive Ortholog Pipeline
Transitive Ortholog Pipeline
Sus scrofa (pig):
CDKN2B (cyclin dependent kinase inhibitor 2B) Transitive Ortholog Pipeline
Transitive Ortholog Pipeline
Other homologs 2
Homo sapiens (human):
CDKN2A (cyclin dependent kinase inhibitor 2A) HGNC
OMA, OrthoDB
Alliance orthologs 3
Mus musculus (house mouse):
Cdkn2b (cyclin dependent kinase inhibitor 2B)
Alliance
DIOPT (Ensembl Compara, Hieranoid, InParanoid, OMA, OrthoFinder, OrthoInspector, PANTHER, PhylomeDB)
Homo sapiens (human):
CDKN2B (cyclin dependent kinase inhibitor 2B)
Alliance
DIOPT (Ensembl Compara, HGNC, Hieranoid, InParanoid, OMA, OrthoFinder, OrthoInspector, PANTHER, PhylomeDB)
Danio rerio (zebrafish):
cdkn2a/b (cyclin-dependent kinase inhibitor 2A/B (p15, inhibits CDK4))
Alliance
DIOPT (Ensembl Compara, Hieranoid, OMA, OrthoFinder, OrthoInspector, PhylomeDB)
Is Marker For:
QTLs:
Tcas11
Latest Assembly:
Rnor_6.0 - RGSC Genome Assembly v6.0
Position:
Rat Assembly Chr Position (strand) Source Genome Browsers JBrowse NCBI UCSC Ensembl Rnor_6.0 5 107,834,353 - 107,857,428 (-) NCBI Rnor6.0 Rnor_6.0 rn6 Rnor6.0 Rnor_5.0 5 111,817,188 - 111,826,334 (-) NCBI Rnor5.0 Rnor_5.0 rn5 Rnor5.0 RGSC_v3.4 5 108,939,669 - 108,945,293 (-) NCBI RGSC3.4 rn4 RGSC3.4 RGSC_v3.1 5 108,946,492 - 108,950,551 (-) NCBI Celera 5 102,728,741 - 102,734,427 (-) NCBI Celera Cytogenetic Map 5 q32 NCBI
JBrowse:
View Region in Genome Browser (JBrowse)
Model
Disease Annotations
RGD Manual Annotations
acute myeloid leukemia susceptibility ISO RGD:1348731 11251739 DNA:hypermethylation: : RGD acute myeloid leukemia ISO RGD:1348731 11252196 mRNA:decreased expression:granulocyte, monocyte: RGD acute myeloid leukemia treatment ISO RGD:1348731 11252164 DNA:hypermethylation:promoter: RGD acute myeloid leukemia disease_progression ISO RGD:1348731 11251749 DNA:deletion: : RGD acute myeloid leukemia disease_progression ISO RGD:1348731 11252161 DNA:hypermethylation:promoter: RGD acute myeloid leukemia ISO RGD:731792 11252167 RGD acute myelomonocytic leukemia ISO RGD:731792 11252167 RGD acute promyelocytic leukemia disease_progression ISO RGD:1348731 11252187 DNA:hyprmethylation:promoter: RGD cervix uteri carcinoma in situ ISO RGD:1348731 2289695 protein:increased expression:uterine cervix RGD chronic myelomonocytic leukemia ISO RGD:1348731 11252180 DNA:altered methylation:5'UTR: RGD cutaneous T cell lymphoma disease_progression ISO RGD:1348731 8552306 DNA:deletion (human) RGD endometrial cancer IAGP 2316081 DNA:deletion (rat) RGD Endometrial Neoplasms ISO RGD:1348731 7248756 DNA:SNPs: :rs615552, rs573687 (human) RGD erythema infectiosum ISO RGD:1348731 11252189 associated with Leukemia, Myeloid, Acute, DNA:hypermethylation:promoter: RGD esophagus squamous cell carcinoma ISO RGD:1348731 7248756 DNA:SNPs: :rs615552, rs573687 (human) RGD granulosa cell tumor ISO RGD:1348731 2296066 RGD lung non-small cell carcinoma disease_progression ISO RGD:1348731 13673922 DNA:hypermethylation:promoter RGD lymphocytic leukemia ISO RGD:731792 11252194 DNA:hypermethylation:promoter: RGD Mesothelioma IAGP 7248760 DNA:deletion RGD myelodysplastic syndrome treatment ISO RGD:1348731 11252169 DNA:altered methylation:promoter: RGD myelodysplastic syndrome disease_progression ISO RGD:1348731 11252195 DNA:hypermethylation: : RGD myelodysplastic syndrome ISO RGD:1348731 11251750 DNA:altered methylation: : RGD open-angle glaucoma disease_progression ISO RGD:1348731 8548689 DNA:SNP: :rs1063192 (human) RGD Ovarian Neoplasms ISO RGD:1348731 2296065 DNA, mRNA:hypermethylation, decreased expression:promoter, ovary RGD prostate cancer disease_progression ISO RGD:1348731 2289684 protein:increased expression:prostate gland RGD renal cell carcinoma IAGP 7248758 DNA:loss of heterozygosity, deletion RGD squamous cell carcinoma ISO RGD:1348731 8548686 protein:decreased expression:skin RGD Tongue Neoplasms IAGP 1578522 DNA:loss of heterozygosity RGD transitional cell carcinoma ISO RGD:1348731 2289697 mRNA:decreased expression:urinary bladder RGD urinary bladder cancer disease_progression ISO RGD:1348731 7248757 DNA:deletion RGD urinary bladder cancer ISO RGD:1348731 2289696 DNA:deletion:urinary bladder RGD Uterine Cervical Neoplasms ISO RGD:1348731 2289695 protein:increased expression:uterine cervix RGD
Imported Annotations - ClinVar
schizophrenia ISO RGD:1348731 8554872 ClinVar Annotator: match by term: Schizophrenia ClinVar PMID:21681106 , PMID:30208311
Imported Annotations - CTD
coronary artery disease ISO RGD:1348731 11554173 CTD Direct Evidence: marker/mechanism CTD PMID:23104008 glaucoma ISO RGD:1348731 11554173 CTD Direct Evidence: marker/mechanism CTD PMID:21532571 lymphoma ISO RGD:1348731 11554173 CTD Direct Evidence: marker/mechanism CTD PMID:9488045 malignant glioma ISO RGD:1348731 11554173 CTD Direct Evidence: marker/mechanism CTD PMID:19578366 , PMID:19578367 myelodysplastic syndrome ISO RGD:1348731 11554173 CTD Direct Evidence: marker/mechanism CTD PMID:17294728 Poisoning ISO RGD:1348731 11554173 CTD Direct Evidence: marker/mechanism CTD PMID:20044985
(+)-schisandrin B multiple interactions EXP 6480464 schizandrin B inhibits the reaction [Carbon Tetrachloride results in increased expression of CDKN2B mRNA] CTD PMID:31150632 1,2-dimethylhydrazine multiple interactions ISO RGD:731792 6480464 [NFE2L2 protein affects the susceptibility to 1, 2-Dimethylhydrazine] which results in decreased expression of CDKN2B mRNA CTD PMID:26388957 1-naphthyl isothiocyanate increases expression EXP 6480464 1-Naphthylisothiocyanate results in increased expression of CDKN2B mRNA CTD PMID:30723492 17beta-estradiol multiple interactions ISO RGD:1348731 6480464 [Estradiol co-treated with EGF protein] results in decreased expression of CDKN2B mRNA more ... CTD PMID:20660070 more ... 17beta-estradiol increases expression ISO RGD:1348731 6480464 Estradiol results in increased expression of CDKN2B mRNA CTD PMID:23094148 17beta-estradiol decreases expression ISO RGD:1348731 6480464 Estradiol results in decreased expression of CDKN2B mRNA CTD PMID:24758408 2,2',4,4'-Tetrabromodiphenyl ether increases expression ISO RGD:1348731 6480464 2 more ... CTD PMID:26988655 2,3,7,8-tetrachlorodibenzodioxine decreases expression ISO RGD:1348731 6480464 Tetrachlorodibenzodioxin results in decreased expression of CDKN2B mRNA, Tetrachlorodibenzodioxin results in decreased expression of CDKN2B protein CTD PMID:17070097 2,3,7,8-tetrachlorodibenzodioxine increases expression ISO RGD:731792 6480464 Tetrachlorodibenzodioxin results in increased expression of CDKN2B mRNA CTD PMID:16611356 , PMID:20805476 2,3,7,8-tetrachlorodibenzodioxine affects expression ISO RGD:1348731 6480464 Tetrachlorodibenzodioxin affects the expression of CDKN2B mRNA CTD PMID:22298810 2,3,7,8-tetrachlorodibenzodioxine decreases expression ISO RGD:731792 6480464 Tetrachlorodibenzodioxin results in decreased expression of CDKN2B mRNA CTD PMID:19770486 2-acetamidofluorene increases expression ISO RGD:731792 6480464 2-Acetylaminofluorene results in increased expression of CDKN2B mRNA CTD PMID:17317680 2-acetamidofluorene increases expression EXP 6480464 2-Acetylaminofluorene results in increased expression of CDKN2B mRNA CTD PMID:22213190 2-hydroxypropanoic acid increases expression ISO RGD:1348731 6480464 Lactic Acid results in increased expression of CDKN2B mRNA CTD PMID:30851411 4,4'-diaminodiphenylmethane decreases expression ISO RGD:731792 6480464 4, 4'-diaminodiphenylmethane results in decreased expression of CDKN2B mRNA CTD PMID:18648102 4-hydroxyphenyl retinamide decreases expression ISO RGD:731792 6480464 Fenretinide results in decreased expression of CDKN2B mRNA CTD PMID:28973697 5-azacytidine decreases methylation ISO RGD:1348731 6480464 Azacitidine results in decreased methylation of CDKN2B promoter CTD PMID:19194470 5-azacytidine multiple interactions ISO RGD:1348731 6480464 [metacept-1 co-treated with Azacitidine] results in increased expression of CDKN2B CTD PMID:19148494 5-azacytidine affects response to substance ISO RGD:1348731 6480464 CDKN2B promoter modified form affects the susceptibility to Azacitidine CTD PMID:17611569 7,12-dimethyltetraphene increases expression EXP 6480464 9 more ... CTD PMID:19480007 afimoxifene multiple interactions ISO RGD:1348731 6480464 afimoxifene inhibits the reaction [Estrogens results in decreased expression of CDKN2B mRNA] CTD PMID:21233418 aflatoxin B1 affects expression ISO RGD:1348731 6480464 Aflatoxin B1 affects the expression of CDKN2B protein CTD PMID:20106945 aflatoxin B1 increases expression EXP 6480464 Aflatoxin B1 results in increased expression of CDKN2B mRNA CTD PMID:25378103 aflatoxin B1 increases expression ISO RGD:1348731 6480464 Aflatoxin B1 results in increased expression of CDKN2B mRNA CTD PMID:21641981 , PMID:27153756 all-trans-retinoic acid increases expression ISO RGD:1348731 6480464 Tretinoin results in increased expression of CDKN2B mRNA CTD PMID:17138961 more ... ammonium chloride affects expression EXP 6480464 Ammonium Chloride affects the expression of CDKN2B mRNA CTD PMID:16483693 arotinoid acid multiple interactions ISO RGD:1348731 6480464 4-(2-(5 more ... CTD PMID:12421932 arsane decreases expression ISO RGD:1348731 6480464 Arsenic results in decreased expression of CDKN2B mRNA CTD PMID:19945496 arsenic atom decreases expression ISO RGD:1348731 6480464 Arsenic results in decreased expression of CDKN2B mRNA CTD PMID:19945496 arsenic(3+) decreases expression ISO RGD:1348731 6480464 Arsenic results in decreased expression of CDKN2B mRNA CTD PMID:19945496 auraptene affects expression ISO RGD:1348731 6480464 aurapten affects the expression of CDKN2B mRNA CTD PMID:23320178 avobenzone decreases expression ISO RGD:1348731 6480464 avobenzone results in decreased expression of CDKN2B mRNA CTD PMID:31016361 azathioprine increases expression ISO RGD:1348731 6480464 Azathioprine results in increased expression of CDKN2B mRNA CTD PMID:22623647 benzene multiple interactions ISO RGD:1348731 6480464 [Benzene results in increased methylation of CDKN2B promoter] which results in decreased expression of CDKN2B mRNA CTD PMID:20044985 benzene decreases expression ISO RGD:1348731 6480464 Benzene results in decreased expression of CDKN2B mRNA CTD PMID:20044985 benzo[a]pyrene increases expression ISO RGD:1348731 6480464 Benzo(a)pyrene results in increased expression of CDKN2B mRNA CTD PMID:20064835 , PMID:21871943 benzo[a]pyrene multiple interactions ISO RGD:731792 6480464 [chromium hexavalent ion co-treated with Benzo(a)pyrene] affects the expression of CDKN2B mRNA CTD PMID:25820237 benzo[a]pyrene increases expression ISO RGD:731792 6480464 Benzo(a)pyrene results in increased expression of CDKN2B mRNA CTD PMID:19770486 , PMID:22228805 benzo[a]pyrene diol epoxide I increases expression ISO RGD:1348731 6480464 7 more ... CTD PMID:19150397 beta-naphthoflavone multiple interactions EXP 6480464 [Diethylnitrosamine co-treated with beta-Naphthoflavone] results in increased expression of CDKN2B mRNA, isoquercitrin inhibits the reaction [[Diethylnitrosamine co-treated with beta-Naphthoflavone] results in increased expression of CDKN2B mRNA] CTD PMID:21295105 beta-naphthoflavone increases expression EXP 6480464 beta-Naphthoflavone results in increased expression of CDKN2B mRNA CTD PMID:22687991 bis(2-chloroethyl) sulfide increases expression ISO RGD:1348731 6480464 Mustard Gas results in increased expression of CDKN2B mRNA CTD PMID:25102026 bis(2-ethylhexyl) phthalate increases expression ISO RGD:1348731 6480464 Diethylhexyl Phthalate results in increased expression of CDKN2B mRNA CTD PMID:31163220 bisphenol A increases expression ISO RGD:731792 6480464 bisphenol A results in increased expression of CDKN2B mRNA CTD PMID:21932408 bisphenol A increases methylation EXP 6480464 bisphenol A results in increased methylation of CDKN2B gene CTD PMID:28505145 bisphenol A affects expression EXP 6480464 bisphenol A affects the expression of CDKN2B mRNA CTD PMID:25181051 cadmium atom increases expression ISO RGD:731792 6480464 Cadmium results in increased expression of CDKN2B mRNA CTD PMID:24067728 cadmium dichloride increases expression ISO RGD:1348731 6480464 Cadmium Chloride results in increased expression of CDKN2B mRNA CTD PMID:26525392 calciol increases expression ISO RGD:731792 6480464 Cholecalciferol results in increased expression of CDKN2B mRNA CTD PMID:16508948 calcitriol increases expression ISO RGD:1348731 6480464 Calcitriol results in increased expression of CDKN2B mRNA CTD PMID:21592394 calcitriol multiple interactions ISO RGD:1348731 6480464 [Testosterone co-treated with Calcitriol] results in increased expression of CDKN2B mRNA CTD PMID:21592394 cannabidiol increases expression ISO RGD:731792 6480464 Cannabidiol results in increased expression of CDKN2B mRNA CTD PMID:21542829 carbamazepine affects expression ISO RGD:1348731 6480464 Carbamazepine affects the expression of CDKN2B mRNA CTD PMID:25979313 carbon nanotube increases expression ISO RGD:731792 6480464 Nanotubes, Carbon results in increased expression of CDKN2B mRNA CTD PMID:25554681 chromium(6+) increases expression EXP 6480464 chromium hexavalent ion results in increased expression of CDKN2B protein CTD PMID:21621607 chromium(6+) multiple interactions ISO RGD:731792 6480464 [chromium hexavalent ion co-treated with Benzo(a)pyrene] affects the expression of CDKN2B mRNA CTD PMID:25820237 cisplatin multiple interactions ISO RGD:1348731 6480464 [Cisplatin co-treated with Quercetin] results in increased expression of CDKN2B mRNA CTD PMID:27514524 coumestrol multiple interactions ISO RGD:1348731 6480464 [Coumestrol co-treated with 2 more ... CTD PMID:19167446 coumestrol decreases expression ISO RGD:1348731 6480464 Coumestrol results in decreased expression of CDKN2B mRNA CTD PMID:19167446 crocidolite asbestos affects expression ISO RGD:1348731 6480464 Asbestos, Crocidolite affects the expression of CDKN2B mRNA CTD PMID:25757056 crocidolite asbestos decreases expression ISO RGD:1348731 6480464 Asbestos, Crocidolite results in decreased expression of CDKN2B mRNA CTD PMID:29523930 cyclosporin A increases expression ISO RGD:1348731 6480464 Cyclosporine results in increased expression of CDKN2B mRNA CTD PMID:21632981 , PMID:25562108 cylindrospermopsin increases expression ISO RGD:1348731 6480464 cylindrospermopsin results in increased expression of CDKN2B mRNA CTD PMID:23726867 cypermethrin increases expression EXP 6480464 cypermethrin results in increased expression of CDKN2B mRNA CTD PMID:22528246 daunorubicin increases expression ISO RGD:1348731 6480464 Daunorubicin results in increased expression of CDKN2B mRNA CTD PMID:12656675 dichlorine multiple interactions EXP 6480464 [Ozone co-treated with Chlorine] results in decreased expression of CDKN2B mRNA CTD PMID:18636392 dimethylarsinic acid decreases expression EXP 6480464 Cacodylic Acid results in decreased expression of CDKN2B mRNA CTD PMID:17720352 dimethylarsinous acid decreases expression ISO RGD:1348731 6480464 dimethylarsinous acid results in decreased expression of CDKN2B mRNA CTD PMID:19945496 disodium selenite increases expression ISO RGD:1348731 6480464 Sodium Selenite results in increased expression of CDKN2B mRNA CTD PMID:16705456 dorsomorphin multiple interactions ISO RGD:1348731 6480464 [NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDKN2B mRNA CTD PMID:27188386 doxorubicin decreases expression ISO RGD:1348731 6480464 Doxorubicin results in decreased expression of CDKN2B mRNA CTD PMID:29803840 doxorubicin increases expression ISO RGD:1348731 6480464 Doxorubicin results in increased expression of CDKN2B mRNA CTD PMID:30031762 endosulfan increases expression ISO RGD:1348731 6480464 Endosulfan results in increased expression of CDKN2B mRNA CTD PMID:26615145 endosulfan decreases expression EXP 6480464 Endosulfan results in decreased expression of CDKN2B mRNA CTD PMID:29391264 Enterolactone multiple interactions ISO RGD:1348731 6480464 [Coumestrol co-treated with 2, 3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of CDKN2B mRNA CTD PMID:19167446 entinostat increases expression ISO RGD:1348731 6480464 entinostat results in increased expression of CDKN2B mRNA CTD PMID:27188386 fenbendazole increases expression EXP 6480464 Fenbendazole results in increased expression of CDKN2B mRNA CTD PMID:23411599 flavonoids increases expression EXP 6480464 Flavonoids results in increased expression of CDKN2B mRNA CTD PMID:18035473 fluoxetine increases expression ISO RGD:731792 6480464 Fluoxetine results in increased expression of CDKN2B mRNA CTD PMID:21497159 formaldehyde increases expression ISO RGD:1348731 6480464 Formaldehyde results in increased expression of CDKN2B mRNA CTD PMID:20655997 formaldehyde decreases expression EXP 6480464 Formaldehyde results in decreased expression of CDKN2B mRNA CTD PMID:12679049 fumonisin B1 increases expression ISO RGD:731792 6480464 fumonisin B1 results in increased expression of CDKN2B mRNA CTD PMID:16221962 furan increases expression EXP 6480464 furan results in increased expression of CDKN2B mRNA CTD PMID:20562052 more ... gefitinib increases expression ISO RGD:1348731 6480464 gefitinib results in increased expression of CDKN2B mRNA, gefitinib results in increased expression of CDKN2B protein CTD PMID:17513607 genistein increases expression ISO RGD:1348731 6480464 Genistein results in increased expression of CDKN2B mRNA CTD PMID:22228119 harmine decreases expression ISO RGD:1348731 6480464 Harmine results in decreased expression of CDKN2B mRNA CTD PMID:25751815 hydrogen peroxide decreases expression ISO RGD:1348731 6480464 Hydrogen Peroxide results in decreased expression of CDKN2B mRNA CTD PMID:12419474 hydrogen peroxide decreases expression ISO RGD:731792 6480464 Hydrogen Peroxide results in decreased expression of CDKN2B mRNA CTD PMID:14729362 hydroxyurea increases expression ISO RGD:731792 6480464 Hydroxyurea results in increased expression of CDKN2B mRNA CTD PMID:27208086 indole-3-methanol increases expression ISO RGD:1348731 6480464 indole-3-carbinol results in increased expression of CDKN2B CTD PMID:16082211 linalool increases expression ISO RGD:1348731 6480464 linalool results in increased expression of CDKN2B mRNA CTD PMID:19922762 lithium chloride increases expression ISO RGD:1348731 6480464 Lithium Chloride results in increased expression of CDKN2B mRNA CTD PMID:23527032 manganese(II) chloride increases expression EXP 6480464 manganese chloride results in increased expression of CDKN2B mRNA CTD PMID:28801915 mercury dichloride increases expression EXP 6480464 Mercuric Chloride results in increased expression of CDKN2B mRNA CTD PMID:16507785 methamphetamine increases expression EXP 6480464 Methamphetamine results in increased expression of CDKN2B mRNA CTD PMID:15644446 N-[2-(4-bromocinnamylamino)ethyl]isoquinoline-5-sulfonamide multiple interactions ISO RGD:1348731 6480464 N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [TGFB1 protein results in increased expression of CDKN2B mRNA] CTD PMID:16361081 N-nitrosodiethylamine decreases expression ISO RGD:731792 6480464 Diethylnitrosamine results in decreased expression of CDKN2B mRNA CTD PMID:18691550 N-nitrosodiethylamine increases expression ISO RGD:731792 6480464 Diethylnitrosamine results in increased expression of CDKN2B mRNA CTD PMID:24535843 N-nitrosodiethylamine multiple interactions EXP 6480464 [Diethylnitrosamine co-treated with beta-Naphthoflavone] results in increased expression of CDKN2B mRNA, isoquercitrin inhibits the reaction [[Diethylnitrosamine co-treated with beta-Naphthoflavone] results in increased expression of CDKN2B mRNA] CTD PMID:21295105 N-nitrosodiethylamine multiple interactions ISO RGD:731792 6480464 IKBKB protein inhibits the reaction [Diethylnitrosamine results in decreased expression of CDKN2B mRNA] CTD PMID:18691550 N-nitrosodimethylamine increases expression EXP 6480464 Dimethylnitrosamine results in increased expression of CDKN2B mRNA CTD PMID:15138612 nickel dichloride affects expression EXP 6480464 nickel chloride affects the expression of CDKN2B mRNA CTD PMID:22546817 ochratoxin A decreases acetylation ISO RGD:1348731 6480464 ochratoxin A results in decreased acetylation of CDKN2B promoter CTD PMID:29098329 ochratoxin A decreases expression ISO RGD:1348731 6480464 ochratoxin A results in decreased expression of CDKN2B mRNA CTD PMID:30763683 ozone multiple interactions EXP 6480464 [Ozone co-treated with Chlorine] results in decreased expression of CDKN2B mRNA CTD PMID:18636392 palbociclib multiple interactions ISO RGD:1348731 6480464 2-(5-benzo(1, 3)dioxol-5-yl-2-tert-butyl-3H-imidazol-4-yl)-6-methylpyridine hydrochloride inhibits the reaction [palbociclib results in increased expression of CDKN2B protein] CTD PMID:22869556 palbociclib decreases response to substance ISO RGD:1348731 6480464 CDKN2B protein results in decreased susceptibility to palbociclib CTD PMID:22711607 palbociclib increases expression ISO RGD:1348731 6480464 palbociclib results in increased expression of CDKN2B protein CTD PMID:22869556 paracetamol affects expression ISO RGD:1348731 6480464 Acetaminophen affects the expression of CDKN2B mRNA CTD PMID:25458485 paracetamol increases expression ISO RGD:1348731 6480464 Acetaminophen results in increased expression of CDKN2B mRNA CTD PMID:29067470 pentachlorophenol increases expression EXP 6480464 Pentachlorophenol results in increased expression of CDKN2B mRNA CTD PMID:19442831 phenylmercury acetate increases expression ISO RGD:1348731 6480464 Phenylmercuric Acetate results in increased expression of CDKN2B mRNA CTD PMID:26272509 phenylmercury acetate multiple interactions ISO RGD:1348731 6480464 [NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDKN2B mRNA CTD PMID:27188386 phorbol 13-acetate 12-myristate multiple interactions ISO RGD:1348731 6480464 4-(2-(5 more ... CTD PMID:12421932 pirinixic acid multiple interactions ISO RGD:1348731 6480464 [pirinixic acid binds to and results in increased activity of PPARA protein] which results in decreased expression of CDKN2B mRNA CTD PMID:19710929 pirinixic acid multiple interactions ISO RGD:731792 6480464 PPARA protein affects the reaction [pirinixic acid results in increased expression of CDKN2B mRNA] CTD PMID:16221962 pirinixic acid increases expression ISO RGD:731792 6480464 pirinixic acid results in increased expression of CDKN2B mRNA CTD PMID:16221962 pirinixic acid decreases expression ISO RGD:731792 6480464 pirinixic acid results in decreased expression of CDKN2B mRNA CTD PMID:17426115 prednisone increases expression ISO RGD:1348731 6480464 Prednisone results in increased expression of CDKN2B protein CTD PMID:15034294 progesterone multiple interactions ISO RGD:1348731 6480464 [Estradiol co-treated with Progesterone] results in decreased expression of CDKN2B mRNA CTD PMID:20660070 quercetin multiple interactions ISO RGD:1348731 6480464 [Cisplatin co-treated with Quercetin] results in increased expression of CDKN2B mRNA CTD PMID:27514524 quercetin increases expression ISO RGD:1348731 6480464 Quercetin results in increased expression of CDKN2B mRNA CTD PMID:21632981 , PMID:27514524 quercetin 3-O-beta-D-glucofuranoside multiple interactions EXP 6480464 isoquercitrin inhibits the reaction [[Diethylnitrosamine co-treated with beta-Naphthoflavone] results in increased expression of CDKN2B mRNA] CTD PMID:21295105 quercetin 3-O-beta-D-glucopyranoside multiple interactions EXP 6480464 isoquercitrin inhibits the reaction [[Diethylnitrosamine co-treated with beta-Naphthoflavone] results in increased expression of CDKN2B mRNA] CTD PMID:21295105 rac-lactic acid increases expression ISO RGD:1348731 6480464 Lactic Acid results in increased expression of CDKN2B mRNA CTD PMID:30851411 resveratrol multiple interactions ISO RGD:1348731 6480464 [Coumestrol co-treated with resveratrol] results in decreased expression of CDKN2B mRNA CTD PMID:19167446 resveratrol increases expression ISO RGD:1348731 6480464 resveratrol results in increased expression of CDKN2B mRNA CTD PMID:25888808 rifampicin multiple interactions ISO RGD:1348731 6480464 [Rifampin co-treated with NR1I2 protein] results in increased expression of CDKN2B mRNA CTD PMID:21127053 ritonavir increases expression ISO RGD:1348731 6480464 Ritonavir results in increased expression of CDKN2B mRNA CTD PMID:19386116 SB 431542 multiple interactions ISO RGD:1348731 6480464 [NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDKN2B mRNA CTD PMID:27188386 sodium arsenite decreases expression ISO RGD:731792 6480464 sodium arsenite results in decreased expression of CDKN2B mRNA CTD PMID:16014739 sodium arsenite affects expression ISO RGD:731792 6480464 sodium arsenite affects the expression of CDKN2B mRNA CTD PMID:16507464 sodium dichromate increases expression EXP 6480464 sodium bichromate results in increased expression of CDKN2B mRNA CTD PMID:12325037 sorafenib increases expression ISO RGD:731792 6480464 sorafenib results in increased expression of CDKN2B protein CTD PMID:19139124 tert-butyl hydroperoxide decreases expression ISO RGD:1348731 6480464 tert-Butylhydroperoxide results in decreased expression of CDKN2B mRNA CTD PMID:12419474 tert-butyl hydroperoxide decreases expression ISO RGD:731792 6480464 tert-Butylhydroperoxide results in decreased expression of CDKN2B mRNA CTD PMID:14729362 testosterone multiple interactions ISO RGD:1348731 6480464 [Testosterone co-treated with Calcitriol] results in increased expression of CDKN2B mRNA CTD PMID:21592394 testosterone increases expression ISO RGD:1348731 6480464 Testosterone results in increased expression of CDKN2B mRNA CTD PMID:21592394 tetrachloromethane increases expression EXP 6480464 Carbon Tetrachloride results in increased expression of CDKN2B mRNA CTD PMID:31150632 tetrachloromethane multiple interactions EXP 6480464 schizandrin B inhibits the reaction [Carbon Tetrachloride results in increased expression of CDKN2B mRNA] CTD PMID:31150632 thioacetamide increases expression EXP 6480464 Thioacetamide results in increased expression of CDKN2B mRNA CTD PMID:22659510 , PMID:23411599 titanium dioxide decreases expression EXP 6480464 titanium dioxide results in decreased expression of CDKN2B mRNA CTD PMID:30012374 trichostatin A multiple interactions ISO RGD:1348731 6480464 decitabine promotes the reaction [trichostatin A results in increased expression of CDKN2B mRNA] CTD PMID:18718068 trichostatin A increases expression ISO RGD:1348731 6480464 trichostatin A results in increased expression of CDKN2B mRNA CTD PMID:18718068 triclosan decreases expression ISO RGD:1348731 6480464 Triclosan results in decreased expression of CDKN2B mRNA CTD PMID:30510588 urethane decreases expression ISO RGD:731792 6480464 Urethane results in decreased expression of CDKN2B mRNA CTD PMID:12117781 urethane increases expression ISO RGD:1348731 6480464 Urethane results in increased expression of CDKN2B mRNA CTD PMID:28818685 valproic acid multiple interactions ISO RGD:1348731 6480464 [Valproic Acid co-treated with arsenic trioxide] results in increased expression of CDKN2B mRNA CTD PMID:19099629 valproic acid increases expression ISO RGD:1348731 6480464 Valproic Acid results in increased expression of CDKN2B mRNA, Valproic Acid results in increased expression of CDKN2B protein CTD PMID:22083351 more ... vorinostat increases expression ISO RGD:1348731 6480464 vorinostat results in increased expression of CDKN2B mRNA, vorinostat results in increased expression of CDKN2B protein CTD PMID:22083351 zinc dichloride decreases expression ISO RGD:1348731 6480464 zinc chloride results in decreased expression of CDKN2B mRNA CTD PMID:21540303 zoledronic acid increases expression ISO RGD:1348731 6480464 zoledronic acid results in increased expression of CDKN2B mRNA CTD PMID:24714768
Gene-Chemical Interaction Annotations
